120 related articles for article (PubMed ID: 1148032)
21. Comparison of the effects of clofibrate and halofenate (MK-185) in isolated rat hepatocytes.
Homcy CJ; Margolis S
Atherosclerosis; 1974; 19(3):381-91. PubMed ID: 4828566
[No Abstract] [Full Text] [Related]
22. Efficacy and interactions of oxandrolone, halo-fenate and clofibrate in a factorial study on experimental acute nephrotic hyperlipidemia.
Schapel GJ; Edwards KD
J Pharmacol Exp Ther; 1975 Jul; 194(1):274-84. PubMed ID: 1171221
[TBL] [Abstract][Full Text] [Related]
23. The effect of halofenate and clofibrate on aggregation and release of serotonin by human platelets.
Lin CY; Smith S
Life Sci; 1976 Mar; 18(6):563-8. PubMed ID: 1263738
[No Abstract] [Full Text] [Related]
24. Halofenate and clofibrate: mechanism of hypotriglyceridemic action in the rat.
Cenedella RJ; Crouthamel WG
J Lipid Res; 1976 Mar; 17(2):156-66. PubMed ID: 1270931
[TBL] [Abstract][Full Text] [Related]
25. Halofenate, serum lipids, and exercise performance in coronary heart disease.
Aronow WS; Vangrow JS; Nelson WH; Pagano J; Papageorge's NP; Khursheed M; Harding PR; Khemka M
Clin Pharmacol Ther; 1974 Jan; 15(1):67-72. PubMed ID: 4587107
[No Abstract] [Full Text] [Related]
26. [First clinical experiences in therapy of hyperuricemia and hyperlipidemia with the clofibrate derivative MK 185].
Wolfram G; Keller C; Kilani C; Zöllner N
Verh Dtsch Ges Inn Med; 1973; 79():1291-3. PubMed ID: 4597609
[No Abstract] [Full Text] [Related]
27. Halofenate: an effective hypolipemia- and hypouricemia-inducing drug.
Aronow WS; Vangrow JS; Nelson WH; Pagano J; Papageorge's NP; Khursheed M; Harding PR; Khemka M
Curr Ther Res Clin Exp; 1973 Dec; 15(12):902-6. PubMed ID: 4203573
[No Abstract] [Full Text] [Related]
28. Effect of halofenate on serum uric acid.
Aronow WS; Harding PR; Khursheed M; Vangrow JS; Papageorge's NP
Clin Pharmacol Ther; 1973; 14(3):371-3. PubMed ID: 4572799
[No Abstract] [Full Text] [Related]
29. Long-term effect of halofenate on serum lipids.
Aronow WS; Vangrow J; Pagano J; Khemka M; Vawter M; Papageorge's NP
Curr Ther Res Clin Exp; 1974 Sep; 16(9):897-903. PubMed ID: 4214664
[No Abstract] [Full Text] [Related]
30. Clofibrate in type II hyperlipoproteinemia.
Ditzel J; Bang HO
Acta Med Scand; 1976; 200(1-2):55-58. PubMed ID: 183462
[TBL] [Abstract][Full Text] [Related]
31. Changes in serum thyrotropin (TSH) in man during halofenate administration.
Davis PJ; Davis FB; Utiger RD; Kulaga SF
J Clin Endocrinol Metab; 1976 Oct; 43(4):873-81. PubMed ID: 824301
[TBL] [Abstract][Full Text] [Related]
32. Effect of halofenate and clofibrate on growth and lipid synthesis in Saccharomyces cerevisiae.
Greenspan MD; Germershausen JI
J Bacteriol; 1973 Feb; 113(2):847-55. PubMed ID: 4570609
[TBL] [Abstract][Full Text] [Related]
33. A one year double blind study of the effect of halofenate and clofibrate in patients with hyperlipoproteinemia.
Rottiers R; van Egmond J
Acta Clin Belg; 1975; 30(5):398-408. PubMed ID: 1221746
[No Abstract] [Full Text] [Related]
34. Altered insulin and glucagon secretion in treated genetic hyperlipemia: a mechanism of theraphy?
Eaton RP; Oase R; Schade DS
Metabolism; 1976 Mar; 25(3):245-9. PubMed ID: 1250161
[TBL] [Abstract][Full Text] [Related]
35. Newer hypolipidemic compounds.
Kritchevsky D
Adv Exp Med Biol; 1975; 63():135-50. PubMed ID: 1106139
[No Abstract] [Full Text] [Related]
36. The interaction between halofenate and propranolol.
Huffman DH; Azarnoff DL; Shoeman DW; Dujovne CA
Clin Pharmacol Ther; 1976 Jun; 19(6):807-12. PubMed ID: 773588
[TBL] [Abstract][Full Text] [Related]
37. Halofenate versus clofibrate in the management of true diabetes insipidus.
Gattereau A; Davignon J; Verdy M; Lewis W
Can Med Assoc J; 1974 Jun; 110(11):1275-77. PubMed ID: 4834432
[TBL] [Abstract][Full Text] [Related]
38. Studies of the uricosuric action of the hypolipidemic drug halofenate.
Ravenscroft PJ; Sands JM; Emmerson BT
Clin Pharmacol Ther; 1973; 14(4):547-51. PubMed ID: 4723262
[No Abstract] [Full Text] [Related]
39. Comparative study of several hypolipidemic agents related to clofibrate.
Beaumont V; Buxtorf JC; Jacotot B; Beaumont JL
Atherosclerosis; 1974; 20(2):141-53. PubMed ID: 4369878
[No Abstract] [Full Text] [Related]
40. Effect of BM 15.075 on lipoprotein concentrations in different types of hyperlipoproteinaemia.
Olsson AG; Rössner S; Walldius G; Carlson LA; Lang PD
Atherosclerosis; 1977 Jul; 27(3):279-87. PubMed ID: 901625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
